Sponsored by
 |
Wednesday, October 22
2-2:50pm
Location: Galileo 901
CoQ10 Technology Maximized with QH™ and Glavonoid™ and Age-Related Metabolic Risk Factors
Kaneka QH™ (ubiquinol) administration to class IV CV patients
significantly increased plasma Q10 concentration in conjunction with
improved functional status, including substantially increased ejection
fraction and Q10/cholesterol ratios. It also measured higher
bioactivity, physiological response and metabolic effect. Kaneka’s new
Glavonoid™ facilitates healthy body fat composition through optimization
and maintenance of lean visceral fat. Mechanistic evaluation exhibits
suppression of fatty acid synthesis and stimulation of fatty acid
oxidation.
Speaker: Dr. Robert Barry, director of scientific affairs, U.S.,
Kaneka Nutrients |
